(HealthDay News) – Very low testosterone levels impact total lipid oxidation but have no effect on the production of very–low–density lipoprotein–triglycerides (VLDL–TGs), according to a study published online Nov. 27 in Diabetes.

Christian Høst, from the Aarhus University Hospital in Denmark, and colleagues treated 12 healthy young males (mean age, 23.1 years) with a gonadotropin–releasing hormone agonist to induce castration levels of testosterone. Over several days one month later, the men were randomly treated with a gel containing physiological levels of testosterone, supraphysiological levels of testosterone, and placebo as part of a crossover study.

The researchers found that short–term hypogonadism had no effect on the secretion or concentration of VLDL–TGs but was characterized by reduced total lipid oxidation. High physiological testosterone levels increased VLDL–TG secretion under both basal conditions and after application of a hyperinsulinemic–euglycemic clamp.

“These data show that testosterone can act through fast non–genomic pathways in the liver,” Høst and colleagues conclude. “Testosterone is not a major determinant of resting VLDL–TG kinetics in men.”

The study was funded in part by an unconditional research grant from Ipsen Pharma. Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)